For GC patients at high risk of PD, the evolving intraperitoneal chemotherapy, including adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC), have provided an encouraging trend towards improved disease outcomes [ 15 ].
← all excerpts
Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers.
1
—
—